Acetazolamide (Diamox) Production Cost Reports

The report provides detailed analysis essential for establishing an acetazolamide production plant. It encompasses all critical aspects necessary for acetazolamide production, including the cost of acetazolamide production, acetazolamide plant cost, acetazolamide production costs, and the overall acetazolamide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an acetazolamide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Acetazolamide Market Analysis: Demand and Supply Analysis, and Sourcing

Acetazolamide is a pharmaceutical active ingredient that acts as a carbonic anhydrase inhibitor and is marketed under the brand name Diamox. It is a white crystalline powder belonging to the thiadiazole sulfonamide group and is produced through a multi-step synthesis using a thiadiazole intermediate. It is an established, off-patent generic medicine used to treat glaucoma, altitude sickness, certain types of seizures, and fluid retention. It is also included in the World Health Organization's List of Essential Medicines. Its demand is mainly driven by pharmaceutical manufacturers producing tablets, extended-release capsules, and injections.

Acetazolamide buyers are mainly generic and branded pharmaceutical companies that use the active ingredient to manufacture finished medicines. As an off-patent drug, it is supplied by several manufacturers and traded as a generic pharmaceutical ingredient. Its demand remains steady due to its established medical uses, while market conditions are influenced by the cost of specialty intermediates, multi-step synthesis, and compliance with good manufacturing practices (GMP). Acetazolamide demand and analysis covers market consumption trends, key demand drivers, and future demand projections to assess production requirements & market potential.

Acetazolamide is mainly supplied by active pharmaceutical ingredient manufacturers in India and China. Several pharmaceutical and fine-chemical companies produce it, while its key intermediates, including thiadiazole compounds and acetylating and chlorinating agents, are sourced from specialty chemical suppliers. The finished active ingredient is supplied to generic and branded drug manufacturers worldwide. Pricing is competitive due to the presence of multiple producers, particularly in India and China. Buyers generally check the purity, impurity profile, and compliance with relevant pharmacopeial specifications before accepting the material.

Summary of the Product, Grades, and Uses

Acetazolamide, with the molecular formula C4H6N4O3S2, a molar mass of approximately 222 g/mol, and CAS number 59-66-5, is a sulfonamide drug containing a thiadiazole ring, a sulfonamide group, and an acetamido group. It is chemically known as N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide. It appears as a white to off-white crystalline powder, melts with decomposition at around 259 degree Celsius, and has low solubility in water. It acts as a carbonic anhydrase inhibitor and is classified as a diuretic.

Acetazolamide is manufactured and handled as a pharmaceutical active ingredient under strict quality and safety controls. It is stored in sealed, moisture-protected packaging under clean and controlled conditions to maintain its chemical stability and purity. Manufacturing and handling operations follow good manufacturing practice requirements to prevent contamination and ensure consistent product quality. Dust extraction, suitable protective equipment, and proper documentation are also essential during powder handling, storage, and transportation.

Acetazolamide is primarily produced and marketed in pharmaceutical-grade active ingredient form, meeting applicable United States, European, and other pharmacopeia specifications. The main grade is a high-purity white crystalline powder with controlled assay, related substances, residual solvents, and heavy metal levels. Micronized material is also supplied with defined particle-size specifications to meet formulation requirements. The product is packed in suitable pharmaceutical-grade containers with the necessary quality documentation.

Acetazolamide is mainly used in pharmaceutical formulations for treating glaucoma by reducing intraocular pressure and for preventing and treating altitude sickness. It is also used as an adjunct treatment for certain types of epilepsy and in managing edema associated with heart failure or specific medications. Other applications include the treatment of idiopathic intracranial hypertension. Its ability to inhibit carbonic anhydrase and regulate fluid balance supports its use across these therapeutic applications.

Main End-Uses of Acetazolamide

Glaucoma and eye-pressure management are major end-uses of acetazolamide. It is used in pharmaceutical formulations to treat open-angle glaucoma, manage acute angle-closure glaucoma before surgery, and reduce intraocular pressure. Its carbonic anhydrase-inhibiting action reduces fluid production in the eye, helping control eye pressure. This application accounts for a significant share of its use in ophthalmic medicines, where it is supplied as a pharmaceutical-grade active ingredient for tablets, capsules, and injectable formulations.

Altitude sickness and neurological treatments form another important end-use segment for acetazolamide. It is used to prevent and treat acute mountain sickness by helping the body adjust to reduced oxygen levels at high altitudes. It is also used as an adjunct treatment for certain types of epilepsy, idiopathic intracranial hypertension, and periodic paralysis. These applications rely on its ability to influence fluid regulation and acid-base balance, supporting demand from neurological and specialized pharmaceutical formulations.

Edema management and other therapeutic applications represent an additional end-use segment for acetazolamide. It is used as a diuretic to manage fluid accumulation associated with heart failure and certain medications. Other applications include urine alkalinization and selected respiratory and sleep-related conditions. Its ability to inhibit carbonic anhydrase and increase the excretion of bicarbonate and fluids supports its use across these treatments, maintaining demand from a broad range of pharmaceutical formulations.

Acetazolamide Market Risks

Acetazolamide faces pricing and competition risks due to its established generic status. As the drug is off-patent and produced by several manufacturers, particularly in India and China, the active ingredient market faces strong competition and price pressure. Demand remains stable due to its established medical applications, but market growth is limited by its mature status and competition from newer treatments, particularly in glaucoma care. These factors restrict pricing flexibility and keep profit margins relatively low for manufacturers.

Manufacturers also face regulatory, quality, and production cost challenges. Acetazolamide production requires compliance with good manufacturing practices, strict quality standards, proper documentation, and regulatory approvals. Its multi-step synthesis involves hazardous chemicals, including hydrazine and chlorine, which require careful handling and safety controls. Effluent treatment and regulatory compliance further increase operating costs and production complexity.

Acetazolamide Production Process and Main Cost Drivers

The acetazolamide production process runs from a thiadiazole intermediate, through the acetylation of its amino group, the oxidative chlorination of its thiol group to a sulfonyl chloride, and the reaction with ammonia to the sulfonamide, to the purification of the active ingredient to pharmaceutical grade.

1. By Acetylation, Chlorination, and Amination of a Thiadiazole Intermediate: The main input is a 2-amino-5-mercapto-1,3,4-thiadiazole, which is acetylated, converted to a sulfonyl chloride, and reacted with ammonia to acetazolamide.

The process begins with the thiadiazole intermediate and its acetylation. The key heterocyclic intermediate, a 2-amino-5-mercapto-1,3,4-thiadiazole, is made from hydrazine and carbon disulfide, forming the thiadiazole ring with an amino group and a thiol group. The amino group is then acetylated with acetic anhydride, giving an acetamido thiadiazole that still carries the thiol group. This step builds and protects part of the molecule, and making a clean thiadiazole intermediate and acetylating it well set the basis for the rest of the synthesis. The key stages are the oxidative chlorination and the amination. The thiol group on the acetylated thiadiazole is treated with chlorine in water, which oxidizes and chlorinates it to a sulfonyl chloride group. This sulfonyl chloride is then reacted with ammonia, which replaces the chlorine with an amino group to give the sulfonamide, completing the acetazolamide molecule. These two stages build the sulfonamide group that gives the drug its action, and controlling the chlorination and the amination is the heart of the process, since it determines the formation and the purity of the active ingredient.

Purification and finishing complete the process. The crude acetazolamide is purified by recrystallization and washing to a high pharmaceutical purity, with the impurities, the residual solvents, and the heavy metals controlled to the pharmacopeia limits. It is filtered, dried, and milled or micronized to the particle size needed for the dosage form, and fully tested. The hazardous materials and the effluent are handled and treated throughout, and the whole operation is run under good manufacturing practice. The main cost factors are the intermediates and the multi-step synthesis, with purification, compliance, and quality control next.

Main Factors Affecting Acetazolamide Production Cost

The cost of acetazolamide production is mainly influenced by the key intermediates, raw materials, and multi-step synthesis. The thiadiazole intermediate, produced using hydrazine and carbon disulfide, is an important specialty input, while acetic anhydride, chlorine, and ammonia are required for subsequent reaction steps. The synthesis, including acetylation, chlorination, and amination, also requires labor, energy, and processing time. These factors, along with purification and quality control, account for a major share of the production cost.

Good manufacturing practice compliance, product yield, and production scale further affect acetazolamide production costs. Pharmaceutical manufacturing requires validated processes, controlled production areas, documentation, and quality testing, adding to operating expenses. Recrystallization to achieve the required purity and micronization increase processing costs, while lower yields across multiple reaction steps raise material consumption. The safe handling of hazardous chemicals and effluent treatment also contribute to costs. Efficient production at scale helps manufacturers control expenses and maintain cost competitiveness.

Raw Materials for Acetazolamide Production Plant and its Procurement

Acetazolamide production primarily requires a thiadiazole intermediate and several chemical reagents. 2-amino-5-mercapto-1,3,4-thiadiazole is the key intermediate, which can be procured from fine-chemical manufacturers or produced using hydrazine and carbon disulfide. Other major inputs include acetic anhydride for acetylation, chlorine for oxidative chlorination, and ammonia for amination, along with suitable solvents and acids. Reliable sourcing of these materials and safe handling of hazardous chemicals are essential for continuous production.

The quality of the intermediates and reagents directly affects the purity, yield, and production cost of acetazolamide. The thiadiazole intermediate must have consistent quality, as its impurities can carry through subsequent reaction and purification stages. Acetic anhydride, chlorine, ammonia, and other processing chemicals must also meet the required specifications to ensure controlled reactions and consistent product quality. Proper testing of incoming materials helps maintain the final active ingredient within applicable pharmacopeia limits.

Acetazolamide manufacturers generally procure the thiadiazole intermediate from specialized fine-chemical suppliers or produce it in-house using hydrazine and carbon disulfide. Other reagents are sourced from established chemical manufacturers based on quality, availability, and cost. Incoming materials are inspected and tested before use, while appropriate storage and safety systems are required for hazardous inputs. Reliable intermediate suppliers, consistent raw material quality, and integrated production capabilities help improve process control and supply reliability.

Sustainability and Regulatory Requirements

An acetazolamide plant is a pharmaceutical active ingredient site, so its concerns are the safe handling of hazardous materials, solvent recovery, and hazardous effluent. The synthesis uses hydrazine, which is toxic, chlorine, and ammonia, which are contained and handled safely with scrubbing and worker protection. The solvents used in the synthesis and the purification are recovered and reused, which reduces waste and cost. The effluent, which can carry hydrazine, sulfur, and chlorine compounds, is treated before discharge, which is a significant part of the operation. Energy for the synthesis, the recrystallization, and the drying is managed. Handling the hazardous materials safely and treating the effluent are the main environmental points.

The regulatory requirements for acetazolamide are those of a pharmaceutical active ingredient and are strict and central. The active ingredient is made under good manufacturing practice, with clean areas, controlled processes, full documentation, validation, and quality control, and it must meet the United States, European, or other pharmacopeia specifications, with controlled impurities, residual solvents, and heavy metals. The plant and the product are subject to inspection and approval by the drug regulators, and a drug master file or equivalent is filed. The handling of the hazardous materials follows chemical safety rules. Producers hold good manufacturing practice certification and quality and environmental certifications such as ISO 9001 and ISO 14001.

CAPEX and OPEX for an Acetazolamide Production Plant

An acetazolamide production plant is a specialized pharmaceutical facility designed to meet good manufacturing practice (GMP) requirements. The main equipment includes multipurpose reactors for intermediate preparation and the successive synthesis steps, including acetylation, chlorination, and amination. Crystallizers are used for purification and recrystallization, followed by centrifuges or filters, dryers, and mills or micronizers for final processing. Solvent recovery systems reduce solvent consumption, while scrubbers handle chlorine, hydrogen chloride, and ammonia emissions. The plant also requires hazardous effluent treatment facilities to manage waste streams containing hydrazine, sulfur, and chlorine compounds, which further add to acetazolamide plant setup costs. Other facilities include controlled GMP production areas, raw material storage, warehouses, utility systems, and quality control and quality assurance laboratories. These laboratories conduct assay, related-substances, residual-solvent, and particle-size testing.

Acetazolamide production costs are mainly influenced by intermediate and reagent prices, multi-step synthesis, purification, and GMP compliance. The thiadiazole intermediate and other specialty chemicals account for a significant share of raw material costs, while the multiple reaction and purification stages increase processing expenses. Quality control, documentation, cleanroom operations, and regulatory compliance add to recurring operating costs. Other expenses include labor, energy, maintenance, hazardous-material handling, and effluent treatment. The plant requires high initial investment in GMP-compliant production suites, reactors, purification equipment, and quality-control systems. Overall, synthesis and GMP infrastructure account for a major share of the investment, while production costs remain competitive with other off-patent generic active ingredients manufactured in India and China.

Plant Location and Investment Factors

A workable acetazolamide site sits where pharmaceutical manufacturing capability, intermediates, and the regulatory framework come together. The active ingredient is made mainly in India and China, where there is strong generic pharmaceutical and fine-chemical capability, intermediates, and good manufacturing practice and regulatory experience, and where the cost is competitive. A site needs good-manufacturing-practice production suites, a supply of the thiadiazole intermediate and the reagents, hazardous-materials handling, solvent recovery, effluent treatment, and quality systems. Access to the generic drug manufacturers and the regulatory approvals for the main markets is important. The key factor is good manufacturing practice capability and a competitive cost, with a reliable intermediate supply.

For an acetazolamide plant, the first investment decision is the good manufacturing practice capability and the regulatory approvals. Because the product is a pharmaceutical active ingredient, the plant must be built and run to good manufacturing practice and approved by the regulators for the markets it serves, which is the central and costly decision. The second decision is the integration into the thiadiazole intermediate and the supply of the reagents, which affects the cost and the quality. A third is the scale and the competitive cost, since the active ingredient is an off-patent generic. Plant scale and investment should match the generic essential-medicine market and the regulatory requirements.

Major Acetazolamide Producing Regions

Production of acetazolamide follows the generic pharmaceutical industry. India and China are the main producing regions for the active ingredient, with their large generic pharmaceutical and fine-chemical industries, the intermediates, and the good manufacturing practice capability, and they supply the active ingredient worldwide. Europe and North America host some active-ingredient production and the manufacturers of the finished medicines and the brand. The intermediates come from the fine-chemical industry, concentrated in Asia. The finished medicines and the demand are worldwide, as acetazolamide is an essential medicine. A new acetazolamide plant would most likely start in India or China, where the capability, the intermediates, and the competitive cost are available.

Key Acetazolamide Producers

Teva Pharmaceutical Industries

• Produces acetazolamide and a broad range of generic medicines as a leading generic pharmaceutical company based in Israel.
• Makes the active ingredient and the finished medicines to Good Manufacturing Practice.
• Competes on generic scale, quality, and global reach.
• Serves pharmaceutical and healthcare markets worldwide.

Sun Pharmaceutical Industries

• Produces acetazolamide and generic medicines and active ingredients as a large pharmaceutical company in India.
• Makes the active ingredient and finished medicines to Good Manufacturing Practice.
• Competes on generic scale, integration, and competitive cost.
• Serves pharmaceutical markets worldwide.

Ipca Laboratories

• Produces active pharmaceutical ingredients and medicines, including acetazolamide, as an integrated pharmaceutical company in India.
• Makes the active ingredient from intermediates to good manufacturing practice.
• Competes on active-ingredient integration, quality, and competitive supply.
• Serves generic and branded drug manufacturers worldwide.

Zydus Lifesciences

• Produces acetazolamide and generic medicines and active ingredients as a pharmaceutical company in India.
• Makes the active ingredient and finished medicines to Good Manufacturing Practice.
• Competes on generic scale, quality, and cost.
• Serves pharmaceutical markets worldwide.

Indian and Chinese API producers

• Produce acetazolamide active ingredient as specialized active-ingredient manufacturers in India and China.
• Make the active ingredient by multi-step synthesis to good manufacturing practice, often integrated into the intermediates.
• Compete on competitive cost and active-ingredient supply.
• Serve generic drug manufacturers worldwide.

Advanz Pharma

• Supplies acetazolamide under the Diamox brand and as a specialty and generic medicine in several markets.
• Provides the finished medicine, sourcing the active ingredient from manufacturers.
• Competes on the established brand and specialty supply.
• Serves healthcare markets, especially in Europe.